[ad_1]
Mosquito Aedes aegypti, responsible for the transmission of dengue fever
PHOTO: Reproduction / Television Globo
The decrease in the number of dengue cases in Brazil has slowed the development of the vaccine against the disease. Less infected, circulation of the virus in the lower population affects the third and final phase of the clinical study of the vaccine. The problem mainly concerns children aged 2 to 6, the most difficult age group to recruit for testing.
"The difficulty of recruiting into this age group is due to the fact that I need parental permission to participate in these tests." Children as volunteers, and they have always worry about allowing, "said Alexander Precious, director of the Clinical Trials and Pharmacovigilance Division of the Butantan Institute. "But we already have a large number of children in this age group and we think we can get a minimum number of volunteers in a few months."
According to Butantan, the third phase of the clinical study began in 2016 and is underway in 14 clinical research centers spread across five regions of the country and encompbading up to 17,000 volunteers. At that time, 15,500 people had been recruited.
After receiving the vaccine, volunteers are followed for five years to prove the effectiveness of the vaccine. The estimate of the completion of vaccine development began about ten years ago, between six and 15 years old. "The typical time for the development of a vaccine, usually six to 15 years, is much closer to 15. Between 12 and 15 years, the period considered the most recurrent for the development of new vaccines," said Precious.
Butantan, the vaccine developed by the Institute is a bet for global health because it should prevent the four subtypes of the dengue virus, may be indicated in people aged 2 to 59 years and should also function in people who have never had the disease before. . The vaccine is in the third phase of the clinical study and is currently being tested on humans.
Once the phase is over and after the registration of the National Agency of Health Vigilance (Anvisa), the vaccine can be made available to the public.
Butantan vaccine works against the four dengue viruses and freeze-dried (in p), which can be diluted and also stored in refrigerators. "At the time, all data collected during phases two and three confirmed the safety of the vaccine, which resulted in very few adverse effects, similar to 39, other vaccines, "said Precious. "Preliminary results have also shown that with a single dose, the vaccine would be able to boost the immune system of the vaccinated so that it is possible to protect them from all four types of dengue fever."
In order to comment on this page, you must be logged in. This space aims to promote a debate on the subject in question. Comments with offensive and damaging tones and those that are offensive to ethics and morals can be reported, even leading to loss of count. You should not post comments for the purpose of disseminating or encouraging ideas and / or opinions that you may or may not share with others.
